Latest news with #Nyati.Additionally
Economic Times
21-07-2025
- Business
- Economic Times
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Live Events About Anthem Biosciences Anthem Biosciences' financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
21-07-2025
- Business
- Time of India
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Live Events About Anthem Biosciences Anthem Biosciences' financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
